This 2014 multicenter clinical trial assessed the safety and efficacy of allogeneic umbilical cord mesenchymal stem cell transplantation (UC-MSCT) in 40 patients with active and refractory systemic lupus erythematosus (SLE). Patients received intravenous infusions of UC-MSCs on days 0 and 7. The treatment was well tolerated, with no transplantation-related adverse
